Disease Markers / 2014 / Article / Tab 2

Clinical Study

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C

Table 2

Factors associated with rapid virological response and sustained virological response to peginterferon plus ribavirin in chronic hepatitis C patients.

RVR ()Non-RVR () valueSVR () Non-SVR () value

Age (mean ± SD) (yr)53.7 ± 11.555.8 ± 10.00.03253.6 ± 11.156.5 ± 10.80.006
Gender (male/female)237/19979/870.082243/21573/710.634
rs12979860 (CC/CT or TT)312/34110/33<0.001326/4096/270.004
Cirrhosis (%)57 (13%)34 (20%)<0.00151 (11%)40 (28%)<0.001
DM (%)76 (17%)27 (16%)0.41871 (16%)32 (22%)0.075
BMI (kg/m2)24.6 ± 3.7 25.1 ± 3.90.16124.6 ± 3.6 25.1 ± 4.10.161
Log HCV-RNA (IU/mL)5.2 ± 1.06.1 ± 0.6<0.0015.3 ± 1.05.9 ± 0.7<0.001
Genotype 1/non-1126/296137/25<0.001177/26986/52<0.001
RVR (%)370 (81%)66 (46%)<0.001
WBC (103/μL)5.8 ± 1.65.8 ± 1.90.5975.8 ± 1.76.0 ± 4.20.482
N-L ratio1.55 ± 0.821.74 ± 1.050.0321.55 ± 0.751.78 ± 1.240.034
Platelet (104/μL)17.7 ± 5.717.2 ± 6.40.42417.9 ± 5.616.6 ± 6.80.037

RVR: rapid virological response; DM: diabetes mellitus; BMI: body mass index; HCV: hepatitis C virus; RVR: rapid virological response; N-L ratio: neutrophil-lymphocyte ratio.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.